Using REMS to Ram Drugs through the FDA Faster
FDA's use of Risk Evaluation & Mitigation Strategies will require NDA and BLA sponsors to provide more rigorous definitions of patient populations. Former FDA Commissioner Kessler thinks that may break the logjam on approvals. (Sidebar to the article, "Evolution in Strategies for Getting FDA Approvals." ) This is a sidebar to the article, "The New World for New Drug Approvals: Evolution in Strategies for Getting FDA Approvals."
You may also be interested in...
House Democrats criticized the administration’s response to the pandemic in a new report. See what Rep. James Clyburn, chairman of the Select Subcommittee on the Coronavirus Crisis, said about it here.
The Perfectio device marketer came away from the advertising industry’s self-regulatory process with a number of claims intact or mostly untouched, though it discontinued a couple going into the assessment and the National Advertising Division advised against a few others. The firm has pledged to comply “in the spirit of compromise.”
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.